5th Annual Immuno-Oncology 360° Conference: What to Expect

February, 6–8, 2019, Crown Plaza Times Square, New York City, NY

Drs. Axel Hoos (GSK), James Gulley (National Cancer Institute), and Andrew Baum (Citi) are co-chairing the fifth annual Immuno-Oncology 360° (IO360), a multidisciplinary conference addressing the rapid advancement of clinical, scientific, and business developments in IO to help develop therapeutics at an accelerated pace. The 3-day summit takes place February 6–8 at the Crowne Plaza Times Square in New York City. It features 10 plenary sessions with more than 80 speakers and includes more than 10 h of networking. More than 450 attendees who are interested in IO will be present, representing the pharma, biotech, academia, regulatory, and private investment communities.

Day One

This year’s program will kick off with the “Discovery and Preclinical Science” session, which will include an update on IL-10, led by Dr. Aung Naing (Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine at MD Anderson Cancer Center), and Dr. Martin Oft, VP, Preclinical and Clinical Research at ARMO.

Additional presentations include “IDO Inhibition Preclinical Updates;” “Blockade of the Adenosine Pathway: Preclinical, Translational and Clinical Studies with CPI-444, an A2A Receptor Antagonist for Cancer;” “Update on Anti-CD73;” and “NKTR-214: Accessing the IL-2 Pathway for Immune Oncology.”

Next is the “Translational Science and Emerging Biomarkers” session, where Dr. Priti Hegde, Global Franchise Lead, Cancer Immunotherapy Biomarkers at Genentech, opens with a keynote talk on “Biomarker Signaling: Turning Cold Tumors Hot.” The session will include the following presentations: “Prostvac and Lessons Learned about Therapeutic Cancer Vaccines;” “Oncolytic Viruses: Promises, Problems and Solutions;” “Key Central Laboratory Capabilities to Enable Successful Immuno-Oncology Clinical Development;” “Immunosequencing: Expanding beyond MRD and Immuno-Oncology;” “Modeling the Effect of Checkpoint Inhibition on the Tumor Microenvironment Using a Personalized Ex vivo Histoculture Approach.” The session will conclude with a panel discussion on “Next Generation Biomarker and Companion Diagnostics for Predicting Response.”

Following the afternoon break, the “IO Novel Technologies and Innovative Solutions” session will showcase companies that offer technologies and solutions to help stakeholders in the IO field advance developments that provide treatment for patients with cancer.

The 1st day of the summit concludes with the “Financial and Commercial Implications” session led by an expert analyst, Dr. Andrew Baum. This plenary includes an investor perspective on the IO landscape and a panel discussion on “Monetizing Science: Turning an Asset into Value through IPOs.”

Day Two

The second day will begin with the “Trends and Collaborations” session, which includes reports on the IO field from three major industry media publications. These talks will be delivered by Simone Fishburn, PhD, of BioCentury and BioCentury Innovations; Asthika Goonewardene, MBA, of Bloomberg Intelligence; and John D Carroll, of Endpoints News.

Access this article online
Website: www.jipoonline.org
DOI: 10.4103/2590-017X.249502
Quick Response Code:


Received: December, 06. Accepted: December, 12.
The next session on “Business Developments” is hosted by IO360° partner, Solebury Trout. The session opens with a talk on “Insights from Deal Trends: Betting on Tumor Immunology,” led by Dr. Jeff Bockman of Cello Health BioConsulting.

Additional talks include “IO Partnering Strategies in an Increasingly Complex Environment”; “Fundraising in the Current IO Space;” and “The Rational Investor: Understanding IO Investment Decisions.” Following these sessions is an executive “fireside” chat with Ilia Tikhomirov, MBA, CEO of Forbius, who discusses lessons learned from their IPO journey.

The afternoon will begin with a keynote address on “Evolving I-SPY 2 to Optimize Breast Cancer” led by Dr. Laura Esserman of University of California, San Francisco. Next are two concurrent tracks: “Translational Science and Emerging Biomarkers Part II” led by Dr. Ian McCaffery of Janssen and “Clinical Operations for IO Trials” led by Jacqueline Karmel of Roche. The translational science track includes talks on “HexaBody Technology to Enhance Antibody Therapeutics for a Broad Range of Applications in Cancer;” “ADC Mechanisms of Action Used to Inform Combinations;” “Cofactor Genomics Case Study;” and “Novel CARs for Solid Tumors: IL-13.” The clinical operation track includes a talk by Genentech’s Karen Dimick on “An End-to-End Clinical Trial Operations Case Study” and a panel discussion on “Operational Collaborations and Data Management between Multi-Stakeholders.”

The day will conclude with the “IO Imaging Aspects” session led by Dr. Andrea Perrone of Merck. Presentations will include “Whole Body PDL1 PET;” “More Information in the Image: Radiomics, Kinetics, and AI;” “A Regulatory Perspective on Imaging and Immuno-Oncology Trends;” and “Imaging Evaluation for IO Protocols at the Site Level.”

Day Three

The third day of the summit will begin with the following sessions: “A Cancer Veteran Story: Judy Perkins’ Immunotherapy Trial Journey” and “Combining IO Modalities in a Cost Effective, Patient-Beneficial Manner That Unfolds in Our Lifetime.” Next, a new plenary session on next-generation cell therapy includes talks on “CAR-T Therapy for Cancer: Optimization Through Engineering T-cells or Combinations;” “Allogeneic Approaches in Cell Therapy;” “Update on NY-ESO;” “CAR-T Cell Manufacturing; CAR-T Clinical Developments;” and “Improving CAR-T Therapies via Next Generation Technologies.”

After lunch, the “IO Clinical Developments” session, led by Dr. Roy Baynes, PhD, includes talks on “The Unprecedented Expansion of Outcomes Data;” “MSI Case Study on the Investigator/Industry Collaboration that led to the FDA’s 1st Tumor Agnostic Label Approval;” “Preclinical and Early Clinical Experience with ADU-S100/MIW815, a first-in-class STING Agonist for the Treatment of Cancer;” “Update on BCMA BiTE and AMG 330;” and the “Latest Clinical Data on T-Cell Bispecifics.”

The Networking and Partnering

IO360° provides many networking opportunities throughout the event, including the 5th annual networking reception at the end of day 2. All scheduled breaks, including breakfast and luncheons, will be held in the exhibitor hall, which features companies showcasing new technologies and other services designed to help support advancements in IO. Furthermore, a new networking platform – Meeting Mojo – will be available to all attendees to help schedule meetings and facilitate communications with other IO leaders at IO360 to maximize participation at the summit.

For more information and to register for IO360, visit io360summit.com.